• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    December 15, 2023 - FDA Roundup: December 15, 2023

    12/15/23 3:14:20 PM ET
    $DNOW
    Metal Fabrications
    Industrials
    Get the next $DNOW alert in real time by email
    For Immediate Release:
    December 15, 2023

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

    • Today, the FDA updated the breast implants web pages to share the latest information on:
      • Risks and complications related to breast implants 
      • Reports of squamous cell carcinoma (SCC), various lymphomas other than Breast Implants Associated Anaplastic Large Cell Lymphoma( BIA-ALCL), and mesenchymal tumors, including sarcoma.
      • Labeling for approved breast implants.
      • Medical Device Reports posted between January 1, 2008, and June 30, 2023, for systemic symptoms in women with breast implants.
      • Medical Device Reports from U.S and worldwide cases found in literature for breast implants associated with anaplastic large cell lymphoma (BIA-ALCL) and postmarket safety of breast implants.
    • Today, the FDA issued draft guidance intended to help animal drug sponsors pursuing Priority Zoonotic Animal Drug (PZAD) designation for a new animal drug. PZADs are new animal drugs that have the potential to prevent or treat a zoonotic disease in animals, including a vector-borne disease, that has the potential to cause serious adverse health consequences for, or serious or life-threatening diseases in humans. This guidance is intended to expedite the development and review of these drugs. The FDA is accepting public comments on the draft guidance until February 16, 2024. 
    • On Thursday, the FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). The most common adverse reactions (≥25% incidence) in patients receiving belzutifan were decreased hemoglobin, fatigue, musculoskeletal pain, increased creatinine, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, and increased aspartate aminotransferase. View full prescribing information for Welireg.
    • On Thursday, the FDA announced that the Center for Devices and Radiological Health (CDRH) began participating in three new collaborative communities in the medical device ecosystem. These new collaborations focus on topics related to artificial intelligence, infection management, and diagnostic tests.
    • On Thursday, the FDA announced the issuance of nine warning letters to manufacturers and distributors of unapproved antimicrobial drugs for nonfood minor animal species such aquarium fish and pet birds. These products are marketed over the counter without medical oversight, which can contribute to the development of antimicrobial resistance.
    • On Thursday, the FDA updated the public health advisory for the investigation of Listeria monocytogenes linked to peaches, plums, and nectarines, to include a link to the updated recall announcement which now includes a list of retail locations that the FDA has reason to believe received the recalled peaches, plums & nectarines This list will be updated as additional information is collected by the FDA. More information is available in the public health advisory.
    • On Wednesday, the FDA announced it will open the Voluntary Qualified Importer Program (VQIP) application portal for fiscal year (FY) 2025. VQIP is a voluntary fee-based program that provides importers, who achieve and maintain control over the safety and security of their supply chains, the benefits of expedited review and importation of human and animal foods into the United States.  
    • On Wednesday, the FDA approved the PulseSelect Pulse Field Ablation (PFA) system for cardiac electrophysiological mapping (stimulation and recording) and to treat atrial fibrillation (Afib) using electrical pulses to ablate cardiac tissue. According to the Centers for Disease Control and Prevention, it is estimated that 12.1 million people in the United States will have the condition in 2030. The PulseSelect PFA system has several components, including a generator and a loop catheter that ablate tissue with fast electrical pulses that form holes in the thin membrane around each cell (irreversible electroporation) instead of with thermal energy. In 2018, the FDA granted Breakthrough Devices designation to the PulseSelect PFA system because it represented a breakthrough technology that could provide more effective treatment for a life-threatening or irreversibly debilitating condition, among other criteria. Conventional thermal ablation for the treatment of Afib may lead to adverse events such as injury to the esophagus. Today’s approval brings to market an alternative treatment modality that may reduce such risks. The FDA granted approval, subject to certain post-approval study requirements, of the PulseSelect PFA system to Medtronic, Inc.
    • On Wednesday, the FDA announced that the investigation of Salmonella linked to Onions is over and CDC announced that the outbreak has ended. CDC reports a total of 80 illnesses in 23 states. There has been a total of 18 hospitalizations and one death associated with this incident. The last illness onset was November 11, 2023. FDA’s investigation is complete. More information is available in the public health advisory.
    • On Wednesday, the FDA approved eflornithine (IWILFIN, USWM, LLC) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. The most common adverse reactions (≥5%), including laboratory abnormalities, were otitis media, diarrhea, cough, sinusitis, pneumonia, upper respiratory tract infection, conjunctivitis, vomiting, pyrexia, allergic rhinitis, decreased neutrophils, increased ALT, increased AST, hearing loss, skin infection, and urinary tract infection.  This represents the first FDA approval of a therapy intended to reduce the risk of relapse in pediatric patients with HRNB. View full prescribing information for IWILFIN.
    • On Tuesday, the FDA sent a safety alert advising restaurants and retailers not to serve or sell and consumers not to eat chopped clams likely harvested from a prohibited area  in Massachusetts and distributed by Red’s Best.
    • On Tuesday, the FDA authorized marketing for Ankon Technologies’ NaviCam ProScan, software as a medical device. The device is based on artificial intelligence (AI) technology, designed for use with the NaviCam Small Bowel Capsule Endoscopy System. Patients with suspected small bowel bleeding swallow a disposable, single use camera pill, which takes pictures (images) of the small bowel as it travels through the digestive tract. A health care professional then reviews the images to identify any bleeding in the small bowel. NaviCam ProScan is indicated to aid in decreasing the time to review capsule endoscopy images. ProScan uses AI to analyze the images and presents the reader with any images that indicate bleeding. NaviCam ProScan is not intended to replace a thorough review of the video, nor is it intended to replace clinical decision making.

    Related Information

    Related Information
    • FDA Newsroom

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

     
    Get the next $DNOW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNOW

    DatePrice TargetRatingAnalyst
    7/8/2022$13.00Buy
    The Benchmark Company
    11/4/2021$12.00Equal-Weight → Overweight
    Stephens & Co.
    7/16/2021$12.00Hold → Buy
    Stifel
    More analyst ratings

    $DNOW
    Leadership Updates

    Live Leadership Updates

    See more
    • Borets International rebrands to Levare International and announces appointment of new Chief Executive Officer and Chairman

      DUBAI, UAE, May 8, 2023 /PRNewswire/ -- Borets International Limited, a global leader in artificial lift engineering, manufacturing, sales, and servicing of electric submersible pumps (ESP), announced the growing and evolving Company has undergone restructuring to reach this exciting juncture where the international business is a distinct and separate division. Accordingly, the rebranding of the company to Levare International Limited (Levare or Company) better aligns with the forward-thinking mindset of new leadership.  This change reflects our growing portfolio of artificial lift solutions offered to our global clients within the oil & gas, mining, geothermal and municipal industries.

      5/8/23 8:23:00 AM ET
      $DNOW
      $NOV
      $RIG
      Metal Fabrications
      Industrials
      Oil & Gas Production
      Energy
    • NOW Inc. Announces Appointment of Karen David-Green to the Board of Directors

      NOW Inc. (NYSE:DNOW) announced today that Karen David-Green has been appointed to the Company's Board of Directors effective March 24, 2023. Ms. David-Green's term will expire at the 2023 annual stockholders' meeting. Ms. David-Green has served as the Chief Communications, Stakeholder and Sustainability Officer at Expro Group, a publicly traded company listed on the New York Stock Exchange, since 2021. Prior to joining Expro Group, Ms. David-Green was part of Weatherford International plc for ten years, where she last served as Senior Vice President, Stakeholder Engagement & Chief Marketing Officer. Prior to joining the energy industry, Ms. David-Green spent 15 years on Wall Street, where

      3/27/23 6:45:00 AM ET
      $DNOW
      Metal Fabrications
      Industrials
    • NOW Inc. Announces Appointment of Sonya Reed to the Board of Directors

      NOW Inc. (NYSE:DNOW) announced today that Sonya Reed has been appointed to the Company's Board of Directors effective August 11, 2021. Ms. Reed's term will expire at the 2022 annual stockholders' meeting. Ms. Reed has served as the Senior Vice President of Human Resources and Corporate Communications of Phillips 66, a publicly traded company listed on the New York Stock Exchange, since 2015. From 2011 to 2015, Ms. Reed was with General Cable, where she last served as Executive Vice President, Chief Human Resources Officer. Ms. Reed began her career at Zurich Financial Services, where she held several positions of increasing responsibility, the last of which was Vice President of Human Reso

      8/12/21 6:45:00 AM ET
      $DNOW
      Metal Fabrications
      Industrials

    $DNOW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP and General Counsel Chang Raymond W was granted 24,417 shares, increasing direct ownership by 8% to 319,944 units (SEC Form 4)

      4 - DNOW Inc. (0001599617) (Issuer)

      2/27/25 4:05:10 PM ET
      $DNOW
      Metal Fabrications
      Industrials
    • Officer Munson Kelly T. was granted 17,742 shares, increasing direct ownership by 14% to 142,925 units (SEC Form 4)

      4 - DNOW Inc. (0001599617) (Issuer)

      2/27/25 4:05:05 PM ET
      $DNOW
      Metal Fabrications
      Industrials
    • Officer Surratt Fanny R. was granted 8,873 shares, increasing direct ownership by 18% to 59,572 units (SEC Form 4)

      4 - DNOW Inc. (0001599617) (Issuer)

      2/27/25 4:05:03 PM ET
      $DNOW
      Metal Fabrications
      Industrials

    $DNOW
    Financials

    Live finance-specific insights

    See more
    • DNOW Reports First Quarter 2025 Results

      Earnings Conference Call May 7, 2025 8:00 a.m. CT 1 (888) 660-6431 (within North America) 1 (929) 203-2118 (outside North America) Access Code: 7372055 Webcast: ir.dnow.com DNOW Inc. (NYSE:DNOW) announced results for the first quarter ended March 31, 2025. Recent Capital Allocation Actions Repurchased $8 million of common stock in the first quarter of 2025, and $16 million year-to-date, under the $160 million share repurchase program authorized this year Completed acquisition of Natron International Pte. Ltd in April, headquartered in Singapore, which expands our electrical supply capabilities under the MacLean International brand in the Asia Pacific region, serving traditional and re

      5/7/25 6:45:00 AM ET
      $DNOW
      Metal Fabrications
      Industrials
    • DNOW Announces First Quarter 2025 Earnings Conference Call

      DNOW Inc. (NYSE:DNOW) has scheduled a conference call to discuss the results for the first quarter of 2025 on Wednesday, May 7, 2025 at 8:00 am (US Central Time). Financial results for the first quarter ending March 31, 2025 are expected to be released that morning before the market opens. The call will be broadcast through the Investor Relations link on DNOW's web site at ir.dnow.com on a listen-only basis. Listeners should log in prior to the start of the call to register for the webcast. A replay of the call will be available online for thirty days following the conference. Participants may also join the conference call by dialing 1-888-660-6431 within North America or 1-929-203-2118 ou

      4/24/25 6:45:00 AM ET
      $DNOW
      Metal Fabrications
      Industrials
    • DNOW Reports Fourth Quarter and Full-Year 2024 Results

      Earnings Conference Call February 13, 2025 8:00 a.m. CT 1 (800) 715-9871 (within North America) 1 (646) 307-1963 (outside North America) Access Code: 7372055 Webcast: ir.dnow.com DNOW Inc. (NYSE:DNOW) announced results for the fourth quarter and full-year ended December 31, 2024. Recent Capital Allocation Actions Announced a new $160 million share repurchase authorization, double the size of the share repurchase program successfully completed in 2024 Completed acquisition of Trojan Rentals, LLC in the fourth quarter of 2024, for $114 million in cash, enhancing our pump rental offering and industrial automation capabilities in the water transfer and management space Financial H

      2/13/25 6:45:00 AM ET
      $DNOW
      Metal Fabrications
      Industrials

    $DNOW
    SEC Filings

    See more
    • SEC Form 10-Q filed by DNOW Inc.

      10-Q - DNOW Inc. (0001599617) (Filer)

      5/7/25 3:07:35 PM ET
      $DNOW
      Metal Fabrications
      Industrials
    • DNOW Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - DNOW Inc. (0001599617) (Filer)

      5/7/25 6:57:42 AM ET
      $DNOW
      Metal Fabrications
      Industrials
    • SEC Form DEFA14A filed by DNOW Inc.

      DEFA14A - DNOW Inc. (0001599617) (Filer)

      4/4/25 9:07:10 AM ET
      $DNOW
      Metal Fabrications
      Industrials

    $DNOW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by NOW Inc. (Amendment)

      SC 13G/A - DNOW Inc. (0001599617) (Subject)

      2/13/24 5:09:44 PM ET
      $DNOW
      Metal Fabrications
      Industrials
    • SEC Form SC 13G/A filed by NOW Inc. (Amendment)

      SC 13G/A - DNOW Inc. (0001599617) (Subject)

      2/9/24 9:59:03 AM ET
      $DNOW
      Metal Fabrications
      Industrials
    • SEC Form SC 13G/A filed by NOW Inc. (Amendment)

      SC 13G/A - DNOW Inc. (0001599617) (Subject)

      1/22/24 2:03:07 PM ET
      $DNOW
      Metal Fabrications
      Industrials

    $DNOW
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 15, 2023 - FDA Roundup: December 15, 2023

      For Immediate Release: December 15, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the breast implants web pages to share the latest information on: Risks and complications related to breast implants  Reports of squamous cell carcinoma (SCC), various lymphomas other than Breast Implants Associated Anaplastic Large

      12/15/23 3:14:20 PM ET
      $DNOW
      Metal Fabrications
      Industrials
    • October 24, 2023 - FDA Roundup: October 24, 2023

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Friday, the FDA approved Medtronic’s Aurora EV-ICD System for the treatment of patients who have experienced, or are at significant risk of developing, life-threatening abnormally fast heart rhythms (ventricular tachyarrhythmias). The system is composed of

      10/24/23 2:26:32 PM ET
      $DNOW
      Metal Fabrications
      Industrials
    • June 9, 2023 - FDA Roundup: June 9, 2023

      For Immediate Release: June 09, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA provided information to health care providers and facilities on oxygenator devices used in extracorporeal circulation. The FDA issued this letter to help ensure that health care providers and facilities are aware of a recall notice by Getinge/Maque

      6/9/23 3:24:13 PM ET
      $DNOW
      Metal Fabrications
      Industrials

    $DNOW
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $DNOW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DNOW Reports First Quarter 2025 Results

      Earnings Conference Call May 7, 2025 8:00 a.m. CT 1 (888) 660-6431 (within North America) 1 (929) 203-2118 (outside North America) Access Code: 7372055 Webcast: ir.dnow.com DNOW Inc. (NYSE:DNOW) announced results for the first quarter ended March 31, 2025. Recent Capital Allocation Actions Repurchased $8 million of common stock in the first quarter of 2025, and $16 million year-to-date, under the $160 million share repurchase program authorized this year Completed acquisition of Natron International Pte. Ltd in April, headquartered in Singapore, which expands our electrical supply capabilities under the MacLean International brand in the Asia Pacific region, serving traditional and re

      5/7/25 6:45:00 AM ET
      $DNOW
      Metal Fabrications
      Industrials
    • EnerCom Opens Registration for the 30th Annual EnerCom Denver - The Energy Investment Conference

      Join us as we celebrate three decades of bringing together the energy industry's companies, investors, analysts, and industry leaders! Investors are encouraged to register for EnerCom Denver – The Energy Investment Conference featuring a broad group of public and private energy companies at www.enercomdenver.com  A robust list of companies has confirmed their participation, and more are being added daily   Sponsorship opportunities are available for companies seeking to increase marketplace and brand awareness through EnerCom's multi-digital approach before, during, and after each event DENVER, April 29, 2025 /PRNewswire/ -- EnerCom, Inc. today opened registration for its 30th annual EnerCo

      4/29/25 1:17:00 PM ET
      $AMPY
      $BKV
      $BRY
      $BTE
      Oil & Gas Production
      Energy
      Metal Fabrications
      Industrials
    • DNOW Announces First Quarter 2025 Earnings Conference Call

      DNOW Inc. (NYSE:DNOW) has scheduled a conference call to discuss the results for the first quarter of 2025 on Wednesday, May 7, 2025 at 8:00 am (US Central Time). Financial results for the first quarter ending March 31, 2025 are expected to be released that morning before the market opens. The call will be broadcast through the Investor Relations link on DNOW's web site at ir.dnow.com on a listen-only basis. Listeners should log in prior to the start of the call to register for the webcast. A replay of the call will be available online for thirty days following the conference. Participants may also join the conference call by dialing 1-888-660-6431 within North America or 1-929-203-2118 ou

      4/24/25 6:45:00 AM ET
      $DNOW
      Metal Fabrications
      Industrials
    • The Benchmark Company initiated coverage on Now with a new price target

      The Benchmark Company initiated coverage of Now with a rating of Buy and set a new price target of $13.00

      7/8/22 7:15:53 AM ET
      $DNOW
      Metal Fabrications
      Industrials
    • NOW upgraded by Stephens & Co. with a new price target

      Stephens & Co. upgraded NOW from Equal-Weight to Overweight and set a new price target of $12.00

      11/4/21 7:03:09 AM ET
      $DNOW
      Metal Fabrications
      Industrials
    • NOW upgraded by Stifel with a new price target

      Stifel upgraded NOW from Hold to Buy and set a new price target of $12.00

      7/16/21 4:55:30 AM ET
      $DNOW
      Metal Fabrications
      Industrials